Mustang Bio (MBIO) Stock Price, News & Analysis

Company Overview

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for oncology and rare genetic diseases. The company’s pipeline includes chimeric antigen receptor T-cell (CAR-T) candidates and adeno‐associated virus (AAV)–based gene therapies designed to address high unmet medical needs. Mustang Bio’s research efforts center on harnessing the body’s immune system to target and eradicate malignant or dysfunctional cells, as well as delivering corrective genetic material to restore or improve patient health in inherited disorders.

The company’s lead oncology candidate, MB-101, is a CAR-T therapy targeting interleukin-13 receptor alpha 2 (IL13Rα2) in glioblastoma multiforme. In parallel, Mustang Bio is advancing MB-102, an AAV-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and MB-107, an AAV-based gene therapy for X-linked severe combined immunodeficiency (SCID-X1). These programs are supported by clinical collaborations with leading academic institutions and research centers, including partnerships to enhance manufacturing processes and accelerate regulatory filings.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Mustang Bio operates facilities in both the United States and Europe to support its global development strategy. The company leverages its proprietary platform technologies and scalable manufacturing capabilities to advance multiple programs simultaneously, while maintaining regulatory interaction across North America and the European Union. Mustang Bio’s operations emphasize rigorous clinical trial design, patient safety, and data transparency to drive timely progress toward potential regulatory approvals.

Under the leadership of President and CEO Manuel Litchman, Ph.D., Mustang Bio is guided by a management team with extensive experience in biotech research, clinical development, and regulatory affairs. Co-founder and Chief Scientific Officer Guido Ferrari, M.D., Ph.D., spearheads the company’s R&D efforts, while Chief Medical Officer Scott Myers, M.D., oversees clinical strategy and trial execution. Mustang Bio’s leadership combines scientific expertise with strategic vision to advance transformative therapies from the laboratory to the clinic.

Key Stats

• Today's Range: $2.50 to $3.00
• 50-Day Range: $0.96 to $3.34
• 52-Week Range: $0.89 to $24.00
• Volume: 1.44 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $11.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mustang Bio Stock Analysis - MarketRank™

Mustang Bio scored higher than 23% of companies evaluated by MarketBeat, and ranked 847th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mustang Bio.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mustang Bio are expected to grow in the coming year, from ($35.00) to ($19.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mustang Bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mustang Bio is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 71.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mustang Bio does not currently pay a dividend.

Dividend Growth

Mustang Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.03% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 71.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.24

News Sentiment

Mustang Bio has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Mustang Bio this week, compared to 1 article on an average week.

Search Interest

7 people have searched for MBIO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

5 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mustang Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.21% of the stock of Mustang Bio is held by insiders.

Percentage Held by Institutions

Only 9.95% of the stock of Mustang Bio is held by institutions.

MBIO Stock Analysis - Frequently Asked Questions

How have MBIO shares performed this year?

Mustang Bio's stock was trading at $8.85 on January 1st, 2025. Since then, MBIO stock has decreased by 70.1% and is now trading at $2.65.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) released its earnings results on Wednesday, May, 14th. The company reported ($0.05) earnings per share for the quarter.

When did Mustang Bio's stock split?

Mustang Bio's stock reverse split on the morning of Thursday, January 16th 2025.The 1-50 reverse split was announced on Tuesday, January 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBIO
• CIK: 1680048
• Web: www.mustangbio.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($78.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -80.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.11) per share
• Price / Book: -1.26

Miscellaneous

• Outstanding Shares: 4,378,000
• Free Float: 4,369,000
• Market Cap: $11.60 million
• Optionable: Not Optionable
• Beta: 2.16